KRAS and pancreatic intraductal papillary-mucinous neoplasm: Sequencing technologies enable comprehensive cancer genome profiling using PJ and efficient detection of tumor suppressor mutations, including TP53, KRAS, and GNAS mutations, serving as a tool to stratify tumor grades in patients with IPMN [117, 118].